A Pembroke, Ont., woman who was found guilty of impaired driving causing death in 2015 has lost her dentist’s licence for six months.
According to the Royal College of Dental Surgeons of Ontario, Christy Natsis will also be monitored for the next two and half years through office visits, pay $7,500 in costs to the college and receive an official reprimand.
The college cited Natsis breaking the law and acting with “disgraceful, dishonourable, unprofessional or unethical conduct.”
Those allegations were uncontested, a spokesperson for the college said, and the hearing proceeded with an agreed statement of facts and a joint submission for the penalty.
The college held a teleconference on Thursday and announced its decision.
Natsis was found guilty in May 2015 — after a 55-day trial that stretched over three years — of impaired driving causing death and dangerous driving causing death in the March 2011 crash that killed Bryan Casey.
She was eventually sentenced to five years in prison, which she unsuccessfully appealed.
MELBOURNE, Australia and HONG KONG, Nov. 02, 2020 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces it has entered into a strategic licence and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited (‘China Grand Pharma’) for Telix’s portfolio of Molecularly-Targeted Radiation (‘MTR’) products.
Telix has appointed China Grand Pharma as its exclusive partner for the Greater China market (‘Territory’)1 and grants China Grand Pharma exclusive development and commercialisation rights to Telix’s portfolio of prostate, renal and brain (glioblastoma) cancer imaging and therapeutic MTR products in the Territory.
Leveraging off China Grand Pharma’s capabilities and infrastructure in China, Telix will enter a significant oncology market, and by partnering with Telix, China Grand Pharma will build on its pipeline of innovative products for Greater China, as well as its strategy in Nuclear Medicine.
The material terms of the partnership include:
US$25M (~AU$35M) up-front non-refundable prepayment to Telix, to be credited against future regulatory and commercial milestone payments.
Up to US$225M (~AU$315M) in regulatory and commercial milestone payments to Telix, across Telix’s existing therapeutic products portfolio.
Program-related investment estimated at up to US$65M (~AU$90M) for clinical costs associated with the development of the therapeutic products in the Territory, to align with Telix’s global clinical development programs.
Royalties on therapeutic product sales in the Territory, in addition to milestone payments.
TLX250-CDx (89Zr-Girentuximab) for renal cancer, and;
TLX591-CDx (68Ga-PSMA), TLX599-CDx (99Tc-PSMA) for prostate cancer.
Strategic Equity Investment
Additionally, China Grand Pharma will make a simultaneous one-time strategic equity investment of US$25M (~AU$35M) in Telix. The investment is in the form of a private placement to China Grand Pharma of 20,947,181 fully paid ordinary Telix shares representing a post-issue holding by China Grand Pharma of 7.62%. Shares will be issued at a price of AU$1.69, based on the 10-day volume-weighted average price (‘VWAP’) for Telix shares up to and including 28th October 2020. Shares will be issued no later than November 06 2020, following receipt of the placement proceeds. Shares issued to China Grand Pharma are subject to a holding lock and will not be able to be traded for a period of 12 months from the date of issue. In addition, China Grand Pharma is subject to a standstill provision and is unable to trade in Telix shares for a period of 12 months.
Telix Pharmaceuticals CEO, Dr. Chris Behrenbruch stated, “Telix’s mission is to be a leading global oncology company and China is an important future market for our products. We are pleased to be working with China Grand Pharma to deliver our diagnostic imaging and therapeutic products to cancer patients in China. Considering the successful acquisition of Sirtex Medical Limited with joint venture private equity partner CDH Genetech Limited2 and subsequent approval of a New Drug Application filing for SIR-Spheres® by the National Medical Products Administration (‘NMPA’) of the